Eight months after Sanofi’s former chief medical officer, Dietmar Berger, M.D., departed, the French drugmaker has selected ...

A newly published report developed by a group of partners, including Sanofi, shines a light on the far-reaching impacts of ...

Publicis Health Media, a 2025 MM+M Agency 100 honoree, named Spark Foundry alum Brad Liebow as chief investment officer.

Sanofi (NASDAQ: SNY) is one of the Most Undervalued International Stocks According to Analysts. On August 14, Sanofi ...

Sanofi (ENXTPA:SAN) has made a move that is bound to get investors talking, as shares edged up just over 5% in the past week. While there is no headline-making event at play, this uptick arrives after ...

Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a Phase 3 clinical study titled A Phase 3, Randomized, ...

Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a Phase 3 clinical study titled ‘A Phase 3, ...

AMX0035 missed the goals of a study in progressive supranuclear palsy. Elsewhere, Novartis and BioArctic struck a deal, and Genentech started building its first East Coast factory.

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Sanofi has received orphan designation from the European Medicines Agency (EMA) for rilzabrutinib, a reversible covalent ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth expectations for the year, banking on expanded demand for its ...

Sanofi is committing up to $60 million to Gyroscope Therapeutics, a clinical-stage biotech whose lead program could become the first gene therapy for a particular vision loss disorder. The deal ...